Dong, Xl., Gong, Y., Chen, Zz. et al. Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3., Chin. J. Integr. Med. 20, 286–291 (2014). https://doi.org/10.1007/s11655-013-1335-0
Xi-lin Dong, Ying Gong, Zhen-zhen Chen, et al. Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3[J]. Chinese Journal of Integrative Medicine, 2014,20(4):286-291.
Dong, Xl., Gong, Y., Chen, Zz. et al. Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3., Chin. J. Integr. Med. 20, 286–291 (2014). https://doi.org/10.1007/s11655-013-1335-0DOI:
Xi-lin Dong, Ying Gong, Zhen-zhen Chen, et al. Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3[J]. Chinese Journal of Integrative Medicine, 2014,20(4):286-291. DOI: 10.1007/s11655-013-1335-0.
Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3
摘要
To investigate the effect of Delisheng Injection (得力生注射液
DLS)
a Chinese medicinal compound
DLS combined with cis-platinum (DDP)
an active agent used in lung cancer chemotherapy
on a human highly metastatic giant lung carcinoma cell line PGCL3. The suspended PGCL3 cells at 105 /mL cultured in 96-well tissue culture plates were divided into 4 groups: DLS treatment group (2 μL/mL
5 μL/mL
10 μL/mL
25 μL/mL)
DDP treatment group (1 μg/mL
2 μg/mL
5 μg/mL
15 μg/mL)
combined DLS with DDP treatment group (DLS:DDP 2 μL/mL:1 μg/mL
5 μL/mL:2 μg/mL
10 μL/mL:5 μg/mL
25 μL/mL:15 μg/mL) and a control group. The cytotoxicity of DLS with different concentrations (2 μL/mL
5 μL/mL
10 μL/mL
25 μL/mL) on PGCL3 cells was determined by 3-(4
5)-dimethylthiahiazo(-z-y1)-3
5-di-phenytetrazoliumromide (MTT) assay. Effect of DLS on adhesion of PGCL-3 cells was tested by cell-matrigel adhesion assay. Chemotactic movement model of transwell camerula was used to determine the effect of DLS on invasion and migration of PGCL-3 cells. Compared with the control group
DLS (2 μL/mL
5 μL/mL
10 μL/mL
25 μL/mL) could significantly decrease cell proliferation
adhesion
invasion and migration abilities (P <0.05). Cell adhesion
invasion and migration abilities were significantly decreased after combination treatment of DLS:DDP (2 μL/mL:1 μg/mL
5 μL/mL:2 μg/mL
10 μL/mL:5 μg/mL
25 μL/mL:15 μg/mL) compared with DDP single-agent treatment (1 μg/mL
2 μg/mL
5 μg/mL
15 μg/mL
P<0.05)
respectively. DLS single-agent has a satisfying inhibition effect in PGCL3 cell line and DLS might enhance the inhibition effect of DDP on cancer metastasis. Our research provided a experimental basis about the treatment on highly metastatic lung caner.
Abstract
To investigate the effect of Delisheng Injection (得力生注射液
DLS)
a Chinese medicinal compound
DLS combined with cis-platinum (DDP)
an active agent used in lung cancer chemotherapy
on a human highly metastatic giant lung carcinoma cell line PGCL3. The suspended PGCL3 cells at 105 /mL cultured in 96-well tissue culture plates were divided into 4 groups: DLS treatment group (2 μL/mL
5 μL/mL
10 μL/mL
25 μL/mL)
DDP treatment group (1 μg/mL
2 μg/mL
5 μg/mL
15 μg/mL)
combined DLS with DDP treatment group (DLS:DDP 2 μL/mL:1 μg/mL
5 μL/mL:2 μg/mL
10 μL/mL:5 μg/mL
25 μL/mL:15 μg/mL) and a control group. The cytotoxicity of DLS with different concentrations (2 μL/mL
5 μL/mL
10 μL/mL
25 μL/mL) on PGCL3 cells was determined by 3-(4
5)-dimethylthiahiazo(-z-y1)-3
5-di-phenytetrazoliumromide (MTT) assay. Effect of DLS on adhesion of PGCL-3 cells was tested by cell-matrigel adhesion assay. Chemotactic movement model of transwell camerula was used to determine the effect of DLS on invasion and migration of PGCL-3 cells. Compared with the control group
DLS (2 μL/mL
5 μL/mL
10 μL/mL
25 μL/mL) could significantly decrease cell proliferation
adhesion
invasion and migration abilities (P <0.05). Cell adhesion
invasion and migration abilities were significantly decreased after combination treatment of DLS:DDP (2 μL/mL:1 μg/mL
5 μL/mL:2 μg/mL
10 μL/mL:5 μg/mL
25 μL/mL:15 μg/mL) compared with DDP single-agent treatment (1 μg/mL
2 μg/mL
5 μg/mL
15 μg/mL
P<0.05)
respectively. DLS single-agent has a satisfying inhibition effect in PGCL3 cell line and DLS might enhance the inhibition effect of DDP on cancer metastasis. Our research provided a experimental basis about the treatment on highly metastatic lung caner.
Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005;1:243–250.
American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997;15:2996–3108.
Zou ML, Li QY, Zuo FX. Efficacy of Delisheng combined with TP chemotherapy in treatment of advanced non-small cell lung cancer. J Modern Oncol (Chin) 2009;17:274–275.
Zhao D, Liu XJ, Xie Q, Huang ZP, Zou BX, Ge YB. Intensity-modulated radiation combined with Delisheng Injection for naspharyngeal carcinoma. J South Med Univ (Chin) 2006;26:874–875.
Cui J, Nan KJ, Tian T, Guo YH, Zhao N, Wang L. Chinese medicinal compound Delisheng has satisfactory antitumor activity, and is associated with up-regulation of endostatin in hunman hepatocellular carcinoma cell line HepG2 in three-dimensional culture. World J Gastroenterol 2007;13:5432–5439.
Lu CX, Nan KJ, Nie YL, Han YN, Jiao M. Delisheng, a Chinese medicine compound, exerts anti-proliferative and pro-apoptotic effects on HepG2 cells through extrinsic and intrinsic pathways. Mol Biol Rep 2010;37:3407–3412.
Wang J, Wang ZL, Zhu YJ, Guo ZJ, Li LY. A study of lung cancer cell apoptosis induced by V16 and Delisheng. Chin J Integr Tradit West Med (Chin) 1998;37:532–535.
Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 2010;29:465–482.
Liotta LA. Tumor invasion and metastasis role of the extracellar matrix: Rhoads Memorial Award lecture. Cancer Res 1986;46:1–7.
Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippiteli M. Bcl-2 overexpression enhances NF-kB activity and induces MMP-9 transcription in human MCF7ADR breast cancer cells. Int J Cancer 2000;86:188–196.
Scherer RL, McIntyre JO, Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev 2008;27:679–690.
Chang YS, Seo EK, Gyllenhaal C, Block KI. Panax ginseng: a role in cancer therapy? Block Integr Cancer Ther 2003;2:13–33.
Yu CH, Kan SF, Pu HF, Jea Chien E, Wang PS. Apoptotic signaling in bufalin- and cinobufagin-treated androgendependent and- independent human prostate cancer cells. Cancer Sci 2008;98:2467–2476.
Wang JY, Jin Y, Xu ZY, Zheng Z, Wan S. Involvement of caspase-3 activity and survivin downregulation in cinobufocini-induced apoptosis in 549 cells. Exp Biol Med 2009;234:566–572.
McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al. Astragalus-based Chinese herbs and platinum based chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials. J Clin Oncol 2006;24:419–430.
Systematic review of β-Elemene injection as adjunctive treatment for lung cancer
Objectified study on tongue images of patients with lung cancer of different syndromes
Anti-fungal test of composite agastache lotion on seven pathogenic fungi and its clinical application
Dynamic observation and clinical assessment of integrated traditional chinese and western medicine on interleukin-2 system, T Cell and erythrocyte immune system in patients of lung cancer
Effects of 24 Chinese medicinal herbs on nucleic acid, protein and cell cycle of human lung adenocarcinoma cells
相关作者
暂无数据
相关机构
Biomedicine and Health Research Center, Hangzhou Normal University
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University
Institute of Basic Research in Chinical Medicine, China Academy of Chinese Medical Sciences
Guang’anmen Hospital, China Academy of Chinese Medical Sciences
School of Public Health and Family Medicine, Capital Medical University